Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

R. Hirsch, Fred; Varella‐Garcia, Marileila; A. Bunn, Paul; A. Franklin, Wilbur; Dziadziuszko, Rafał; Thatcher, Nick; Y. Chang, Alex; M. Parikh, Purvish; Rodrigues Pereira, José; Ciuleanu, Tudor–Eliade; von Pawel, Joachim; Watkins, Claire; V. Flannery, Angela; Ellison, Gillian; Donald, Emma; Knight, Lucy; V. Parums, Dinah; Botwood, Nicholas; R. Holloway, Brian

doi:10.1200/jco.2006.06.3958

Public

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • Oct 30, 2006

Authors:

Fred R. Hirsch

Marileila Varella‐Garcia

Paul A. Bunn

Abstract

PURPOSE: The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared gefitinib with placebo in 1,692 patients with refractory advanced non-small-cell lung cancer. We analyzed ISEL tumor biopsy samples to examine relationships between biomarkers and clinical outcome after gefitinib ...

Subject

Gefitinib

Medicine

KRAS

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!